BCLI Jul 2024 3.000 call
| Previous close | 0.0300 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 3.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0300 - 0.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
PR NewswireBrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m. U.S. Eastern Time.
- PR Newswire
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor (the "Holder") for the purchase and sale of 11,111,111 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.36 per share in a registered direct offering.
- PR Newswire
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn®, its investigational therapy for amyotrophic lateral sclerosis (ALS).
